Although Pfizer (NYSE:PFE) reiterated 2025 financial guidance issued in December, the midpoints of the ranges for revenue and EPS are below consensus figures. The pharmaceutical giant is projecting ...

Pfizer’s forecast for sales of its COVID-19 vaccine and treatment next year falls more than $5 billion short of the Wall Street consensus. The drugmaker’s sales tumbled in early morning trading.

A messenger RNA combination vaccine that Pfizer and BioNTech are developing for both Covid-19 and influenza posted mixed results in a pivotal study, meeting just one of the two main goals assessing ...

As one of the world’s top pharmaceutical firms, Pfizer (PFE) is liable to see significant movement in its share price based on key fundamental data. However, once the much-anticipated event has passed ...